MET and hepatocellular carcinoma: For example, FGFR-TKIs combined with AKT inhibitors can overcome FGFR1 amplification-mediated EGFR-TKI resistance.110 AKT inhibitors such as MK2206 and capmatinib can overcome sorafenib resistance in HCC with MET mutations.111